{"title":"Pearls & Oy-sters: Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Presenting as Encephalomyelitis With Leptomeningeal Enhancement.","authors":"Alex P Vu,Ronak K Kapadia,Jodie I Roberts","doi":"10.1212/wnl.0000000000213662","DOIUrl":null,"url":null,"abstract":"Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy is an uncommon diagnosis in the differential for leptomeningeal enhancement. This case highlights the presentation, imaging features, and investigations important for diagnosis of GFAP astrocytopathy to ensure timely treatment of this corticosteroid-responsive disease. A 50-year-old man from Hong Kong presented with 10 days of progressive urinary retention, dysarthria, diplopia, and gait ataxia after a viral illness. Initial nonenhanced MRI brain was negative. After he developed encephalopathy, repeat MRI with gadolinium on admission day 6 revealed diffuse basal and spinal cord leptomeningeal enhancement. This imaging pattern, in combination with CSF eosinophilia and epidemiologic risk factors, precipitated empiric treatment for tuberculosis meningitis (including dexamethasone). Extensive investigations for an alternate infectious, autoimmune, or malignant diagnosis were negative. Dexamethasone cessation after a gastrointestinal bleed led to clinical and radiologic deterioration. This prompted further CSF and serum testing, which showed positive CSF GFAP-IgG immunofluorescence assay (IFA) (1:128) solidifying the diagnosis of autoimmune GFAP astrocytopathy. Induction with high-dose corticosteroids, intravenous immunoglobulins, and rituximab produced clinical and radiologic remission. Autoimmune GFAP astrocytopathy is an autoimmune disorder with a characteristic perivascular radial enhancement imaging pattern. However, a variety of other clinical and radiologic presentations may be seen, including leptomeningeal enhancement and T2/FLAIR hyperintensities. Diagnosis is confirmed with CSF GFAP-IgG testing. We provide a differential diagnosis for leptomeningeal enhancement and highlight clinical pearls for the diagnosis and management of autoimmune GFAP astrocytopathy.","PeriodicalId":19256,"journal":{"name":"Neurology","volume":"2 1","pages":"e213662"},"PeriodicalIF":7.7000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/wnl.0000000000213662","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy is an uncommon diagnosis in the differential for leptomeningeal enhancement. This case highlights the presentation, imaging features, and investigations important for diagnosis of GFAP astrocytopathy to ensure timely treatment of this corticosteroid-responsive disease. A 50-year-old man from Hong Kong presented with 10 days of progressive urinary retention, dysarthria, diplopia, and gait ataxia after a viral illness. Initial nonenhanced MRI brain was negative. After he developed encephalopathy, repeat MRI with gadolinium on admission day 6 revealed diffuse basal and spinal cord leptomeningeal enhancement. This imaging pattern, in combination with CSF eosinophilia and epidemiologic risk factors, precipitated empiric treatment for tuberculosis meningitis (including dexamethasone). Extensive investigations for an alternate infectious, autoimmune, or malignant diagnosis were negative. Dexamethasone cessation after a gastrointestinal bleed led to clinical and radiologic deterioration. This prompted further CSF and serum testing, which showed positive CSF GFAP-IgG immunofluorescence assay (IFA) (1:128) solidifying the diagnosis of autoimmune GFAP astrocytopathy. Induction with high-dose corticosteroids, intravenous immunoglobulins, and rituximab produced clinical and radiologic remission. Autoimmune GFAP astrocytopathy is an autoimmune disorder with a characteristic perivascular radial enhancement imaging pattern. However, a variety of other clinical and radiologic presentations may be seen, including leptomeningeal enhancement and T2/FLAIR hyperintensities. Diagnosis is confirmed with CSF GFAP-IgG testing. We provide a differential diagnosis for leptomeningeal enhancement and highlight clinical pearls for the diagnosis and management of autoimmune GFAP astrocytopathy.
期刊介绍:
Neurology, the official journal of the American Academy of Neurology, aspires to be the premier peer-reviewed journal for clinical neurology research. Its mission is to publish exceptional peer-reviewed original research articles, editorials, and reviews to improve patient care, education, clinical research, and professionalism in neurology.
As the leading clinical neurology journal worldwide, Neurology targets physicians specializing in nervous system diseases and conditions. It aims to advance the field by presenting new basic and clinical research that influences neurological practice. The journal is a leading source of cutting-edge, peer-reviewed information for the neurology community worldwide. Editorial content includes Research, Clinical/Scientific Notes, Views, Historical Neurology, NeuroImages, Humanities, Letters, and position papers from the American Academy of Neurology. The online version is considered the definitive version, encompassing all available content.
Neurology is indexed in prestigious databases such as MEDLINE/PubMed, Embase, Scopus, Biological Abstracts®, PsycINFO®, Current Contents®, Web of Science®, CrossRef, and Google Scholar.